Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Mandy Jackson
A federal grand jury indicted Steven Burrill and an associate on charges of fraud and tax evasion regarding investment funds run by the San Francisco-based life science advisor, who settled a related SEC claim in 2016. If convicted, he could spend decades in prison and pay millions in fines.
Synthetic Genomics, co-founded by genomic pioneer Craig Venter, has been sued by its former intellectual property chief for gender discrimination – a claim that CEO Oliver Fetzer believes to be "without merit."
MassBio and Liftstream partnered on a report about women's, men's and companies' views on gender diversity in the life science industry and identified several opportunities for employers to improve, including the need to employ more women in leadership roles to attract female job-seekers.
Medicxi's new $300m venture fund will benefit from the expertise of former GSK R&D leader Moncef Slaoui, while ex-CEO Witty will inform portfolio strategy at Hatteras. Also, Kaleido hires past Cubist CEO and brings VC funding to $65m, while Gilead sells $3bn in debt to fund Kite deal.
BridgeBio's hub-and-spoke model is similar to the Roivant and Fortress strategies, but with a focus on drug candidates for genetic diseases in need of a bridge to future funding.
Biomarkers for psychiatric disorders are lacking, but Astellas is investing in its own and external efforts to identify drug targets as well as patients who'll respond to new therapies.